RAS G12D-MUTATED NSCLC

Clinical trials for RAS G12D-MUTATED NSCLC explained in plain language.

Never miss a new study

Get alerted when new RAS G12D-MUTATED NSCLC trials appear

Sign up with your email to follow new studies for RAS G12D-MUTATED NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Breakthrough trial targets 'Undruggable' lung cancer mutations

Disease control Recruiting now

This clinical trial is testing several new experimental drugs designed to target specific genetic mutations (called RAS mutations) found in advanced non-small cell lung cancer. The study will involve 616 adults whose cancer has progressed despite standard treatments. Researchers …

Matched conditions: RAS G12D-MUTATED NSCLC

Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control

Last updated Mar 09, 2026 14:23 UTC

RAS G12D-MUTATED NSCLC

Get alerted when new RAS G12D-MUTATED NSCLC trials appear

Breakthrough trial targets 'Undruggable' lung cancer mutations